Role of oxidative stress and reactive oxygen radicals in the pathogenesis of systemic sclerosis

Studies on Arthritis and Joint Disorders

Volumn , Issue , 2013, Pages 183-197

  Piera Velazquez, Sonsoles ^a   Jimenez, Sergio A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85028674815     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-6166-1_10     Document Type: Chapter

References (80)

1. Katsumoto TR, Whitfield ML, Connolly MK (2011) The pathogenesis of systemic sclerosis. Annu Rev Pathol 6:509-537
2. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360:1989-2003
3. Jimenez SA, Hitraya E, Varga J (1996) Pathogenesis of scleroderma. Collagen. Rheum Dis Clin North Am 22:647-674
4. Varga JA, Trojanowska M (2008) Fibrosis in systemic sclerosis. Rheum Dis Clin North Am 34:115-143
5. Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28:78-85
6. Herrick AL, Matucci Cerinic M (2001) The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 19:4-8
7. Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento EV (2008) Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. Semin Immunopathol 30:329-337
8. Lundberg AC, Akesson A, Akesson B (1992) Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis 51:1143-1148
9. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI (1994) Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 21:1477-1483
10. Ogawa F, Shimizu K, Muroi E, Hara T, Sato S (2011) Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis. Clin Rheumatol 30:921-925
11. Sambo P, Jannino L, Candela M et al (1999) Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 112:78-84
12. Allanore Y, Borderie D, Perianin A, Lemarechal H, Ekindjian OG, Kahan A (2005) Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis. Arthritis Res Ther 7:R93-R100
13. Servettaz A, Guilpain P, Goulvestre C et al (2007) Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 66:1202-1209
14. Sambo P, Baroni SS, Luchetti M et al (2001) Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 44:2653-2664
15. Avouac J, Borderie D, Ekindjian OG, Kahan A, Allanore Y (2010) High DNA oxidative damage in systemic sclerosis. J Rheumatol 37:2540-2547
16. Tikly M, Marshall SE, Haldar NA, Gulumian M, Wordsworth P, Welsh KI (2004) Oxygen free radical scavenger enzyme polymorphisms in systemic sclerosis. Free Radic Biol Med 36:1403-1407
17. Iwata Y, Yoshizaki A, Ogawa F et al (2009) Increased serum pentraxin 3 in patients with systemic sclerosis. J Rheumatol 36:976-983
18. Morrow JD (2000) The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 32:377-385
19. Stein CM, Tanner SB, Awad JA, Roberts LJ 2nd, Morrow JD (1996) Evidence of free radicalmediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 39:1146-1150
20. Wood LG, Garg ML, Simpson JL et al (2005) Induced sputum 8-isoprostane concentrations in inflammatory airway diseases. Am J Respir Crit Care Med 171:426-430
21. Montuschi P, Ciabattoni G, Paredi P et al (1998) 8-isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 158:1524-1527
22. Shimizu K, Ogawa F, Akiyama Y et al (2008) Increased serum levels of N(epsilon)-(hexanoyl) lysine, a new marker of oxidative stress, in systemic sclerosis. J Rheumatol 35:2214-2219
23. Ogawa F, Shimizu K, Hara T et al (2008) Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: association with fibrosis and vascular damage. Clin Exp Rheumatol 26:659-662
24. Emerit I, Filipe P, Meunier P et al (1997) Clastogenic activity in the plasma of scleroderma patients: a biomarker of oxidative stress. Dermatology 194:140-146
25. Hancock JT, Desikan R, Neill SJ (2001) Role of reactive oxygen species in cell signalling pathways. Biochem Soc Trans 29:345-350
26. Sorescu D, Weiss D, Lassegue B et al (2002) Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105:1429-1435
27. Brandes RP, Weissmann N, Schroder K (2010) NADPH oxidases in cardiovascular disease. Free Radic Biol Med 49:687-706
28. Lassègue B, Griendling KK (2010) NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 30:653-661
29. Griffith B, Pendyala S, Hecker L, Lee PJ, Natarajan V, Thannickal VJ (2009) NOX enzymes and pulmonary disease. Antioxid Redox Signal 11:2505-2516
30. Geiszt M, Kopp JB, Várnai P, Leto TL (2000) Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 97:8010-8014
31. Sorce S, Krause KH (2009) NOX enzymes in the central nervous system: from signaling to disease. Antioxid Redox Signal 11:2481-2504
32. Solans R, Motta C, Sola R et al (2000) Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis Rheum 43:894-900
33. Servettaz A, Goulvestre C, Kavian N et al (2009) Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 182:5855-5864
34. Tsou PS, Talia NN, Pinney AJ et al (2012) Effect of oxidative stress on protein tyrosine phosphatase-1B in scleroderma dermal fibroblasts. Arthritis Rheum 64(6):1978-1989
35. Kawahara T, Quinn MT, Lambeth JD (2007) Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Duox) family of enzymes. BMC Evol Biol 7:109
36. Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87:245-313
37. Sumimoto H (2008) Structure, regulation and evolution of nox-family NADPH oxidases that produce reactive oxygen species. FEBS J 275:3249-3277
38. Cucoranu I, Clempus R, Dikalova A et al (2005) NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myo fibroblasts. Circ Res 97:900-907
39. Hecker L, Vittal R, Jones T et al (2009) NADPH oxidase-4 mediates myo fibroblast activation and fibrogenic responses to lung injury. Nat Med 15:1077-1081
40. Waghray M, Cui Z, Horowitz JC et al (2005) Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myo fibroblasts. FASEB J 19:854-856
41. Roberts AB, Sporn MB, Assoian RK et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167-4171
42. Trojanowska M (2008) Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 47(Suppl 5):v2-v4
43. Lassegue B, Sorescu D, Szocs K et al (2001) Novel gp91(phox) homologues in vascular smooth muscle cells: Nox1 mediates angiotensin II-induced superoxide formation and redoxsensitive signaling pathways. Circ Res 88:888-894
44. Datla SR, Peshavariya H, Dusting GJ, Mahadev K, Goldstein BJ, Jiang F (2007) Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitro. Arterioscler Thromb Vasc Biol 27:2319-2324
45. An SJ, Boyd R, Zhu M, Chapman A, Pimentel DR, Wang HD (2007) NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts. Cardiovasc Res 75:702-709
46. Kawaguchi Y, Takagi K, Hara M et al (2004) Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 50:216-226
47. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H (2000) Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 269:713-717
48. Svegliati S, Olivieri A, Campelli N et al (2007) Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110:237-241
49. Baroni SS, Santillo M, Bevilacqua F et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667-2676
50. Svegliati S, Cancello R, Sambo P et al (2005) Platelet-derived growth factor and reactive oxygen species (ROS) regulate ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 280:36474-36482
51. Wu M, Varga J (2008) In perspective: murine models of scleroderma. Curr Rheumatol Rep 10:173-182
52. Beyer C, Schett G, Distler O, Distler JH (2010) Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 62:2831-2844
53. Rogai V, Lories RJ, Guiducci S, Luyten FP, Matucci Cerinic M (2008) Animal models in systemic sclerosis. Clin Exp Rheumatol 26:941-946
54. Van de Water J, Jimenez SA, Gershwin ME (1995) Animal models of scleroderma: contrasts and comparisons. Int Rev Immunol 12:201-216
55. Jimenez SA, Christner PJ (2002) Murine animal models of systemic sclerosis. Curr Opin Rheumatol 14:671-680
56. Yamamoto T, Takagawa S, Katayama I et al (1999) Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 112:456-462
57. Matsushita M, Yamamoto T, Nishioka K (2005) Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma. Clin Exp Immunol 139:429-438
58. Kajii M, Suzuki C, Kashihara J et al (2011) Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma. Clin Exp Immunol 163:235-241
59. Nakamura-Wakatsuki T, Oyama N, Yamamoto T (2012) Local injection of latency-associated peptide, a linker propeptide specific for active form of transforming growth factor-beta1, inhibits dermal sclerosis in bleomycin-induced murine scleroderma. Exp Dermatol 21:189-194
60. Yamamoto T, Eckes B, Krieg T (2000) Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts. Arch Dermatol Res 292:556-561
61. Nagai M, Hasegawa M, Takehara K, Sato S (2004) Novel autoantibody to Cu/Zn superoxide dismutase in patients with localized scleroderma. J Invest Dermatol 122:594-601
62. Arcucci A, Ruocco MR, Amatruda N et al (2011) Analysis of extracellular superoxide dismutase in fibroblasts from patients with systemic sclerosis. J Biol Regul Homeost Agents 25:647-654
63. Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM (2000) Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology 155:1-15
64. Yoshizaki A, Yanaba K, Ogawa A et al (2011) The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Arthritis Rheum 63:3086-3097
65. Marut WK, Kavian N, Servettaz A et al (2012) The organotelluride catalyst (PHTE)NQ prevents HOCl-induced systemic sclerosis in mouse. J Invest Dermatol 132:1125-1132
66. Kokot A, Sindrilaru A, Schiller M et al (2009) Alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis Rheum 60:592-603
67. Cracowski JL, Girolet S, Imbert B et al (2005) Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement. Free Radic Biol Med 38:98-103
68. Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A (2004) Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med 116:595-600
69. Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE (1979) Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis 38:356-361
70. Sambo P, Amico D, Giacomelli R et al (2001) Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 28:2257-2262
71. Salsano F, Letizia C, Proietti M et al (2005) Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynaud's phenomenon. Int J Immunopathol Pharmacol 18:761-770
72. Rosato E, Zardi EM, Barbano B et al (2009) N-acetylcysteine infusion improves hepatic perfusion in the early stages of systemic sclerosis. Int J Immunopathol Pharmacol 22:763-772
73. Rosato E, Cianci R, Barbano B et al (2009) N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis. Acta Pharmacol Sin 30:1283-1288
74. Rosato E, Rossi C, Molinaro I, Giovannetti A, Pisarri S, Salsano F (2011) Long-term N-acetylcysteine therapy in systemic sclerosis interstitial lung disease: a retrospective study. Int J Immunopathol Pharmacol 24:727-733
75. Dooley A, Shi-Wen X, Aden N et al (2010) Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Rheumatology (Oxford) 49:2024-2036
76. Cao YL, Li X, Zheng M (2010) Capparis spinosa protects against oxidative stress in systemic sclerosis dermal fibroblasts. Arch Dermatol Res 302:349-355
77. Erre GL, De Muro P, Dellaca P et al (2008) Iloprost therapy acutely decreases oxidative stress in patients affected by systemic sclerosis. Clin Exp Rheumatol 26:1095-1098
78. Erre GL, Passiu G (2009) Antioxidant effect of iloprost: current knowledge and therapeutic implications for systemic sclerosis. Reumatismo 61:90-97
79. Volpe A, Biasi D, Caramaschi P et al (2008) Iloprost infusion does not reduce oxidative stress in systemic sclerosis. Rheumatol Int 28:335-337
80. Kalin R, Righi A, Del Rosso A et al (2002) Activin, a grape seed-derived proanthocyanidin extract, reduces plasma levels of oxidative stress and adhesion molecules (ICAM-1, VCAM-1 and E-selectin) in systemic sclerosis. Free Radic Res 36:819-825